secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2021-07-16T23:59:59+00:00
Accession:  0001193125-21-217455
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics increases CEO base salary to $500k, bonus target to 50%
--------------------------------------------------------------------------

- CEO David Campbell's annual base salary increased from $424,408 to $500,000 effective July 15, 2021.
- Annual target performance bonus percentage increased from 40% to 50%, retroactive to beginning of 2021.
- Changes approved by Board of Directors upon Compensation Committee recommendation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312521217455/0001193125-21-217455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312521217455/d139884d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-217455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer